Bitcoin groundbreakers share personal stories of how Bitcoin is changing lives for the better. Host Mauricio Di Bartolomeo, co-founder and CSO of Ledn, speaks with leading Bitcoin voices, entrepreneurs, and human rights advocates to hear their unique journey and practical real-world examples of how Bitcoin has made a positive impact in their lives. Brought to you by Ledn, a leading financial services company built for Bitcoin & digital assets. Ledn offers a suite of lending, saving and tradi ...
…
continue reading
Innehåll tillhandahållet av Proactive Investors. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Proactive Investors eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !
Gå offline med appen Player FM !
OKYO Pharma CEO Announces First Dosing in Phase 2 Trial for OK-101 to Treat Neuropathic Corneal Pain
MP3•Episod hem
Manage episode 446656547 series 2891889
Innehåll tillhandahållet av Proactive Investors. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Proactive Investors eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
OKYO Pharma CEO Gary Jacob joined Steve Darling from Proactive to share news the company is reporting the first patient has been dosed in the Phase 2 trial of OK-101, a topical ocular treatment for neuropathic corneal pain (NCP). This double-masked, randomized, 12-week placebo-controlled trial will enroll 48 patients, all of whom will have their NCP disease confirmed via confocal microscopy. The trial is being conducted at a single center under the leadership of Dr. Pedram Hamrah from Tufts Medical Center, where he serves as Professor and Vice Chair of Research and Academic Programs, and Director of the Center for Translational Ocular Immunology. Dr. Hamrah’s expertise will guide the study, which aims to evaluate the effectiveness of OK-101 in alleviating pain caused by corneal nerve damage—a condition with no current FDA-approved treatments. Jacob highlighted that OK-101 is a novel, non-opioid therapeutic specifically designed to target the severe and often debilitating pain associated with NCP. This condition can stem from various sources, including dry eye disease, surgery, or infections, and can significantly affect patients' quality of life. Presently, treatment options for NCP are limited to temporary pain relief strategies that often fall short of providing long-term relief. OKYO Pharma’s development of OK-101 is a promising step toward addressing this unmet medical need, potentially offering patients a more effective solution to manage their corneal pain. #proactiveinvestors #okyopharmalimited #nasdaq #okyo #NeuropathicPain #OcularPain #OK101Trial #FDAApproval #Biotech #Pharmaceuticals #ClinicalTrial #DrugDevelopment #HealthInnovation#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
609 episoder
OKYO Pharma CEO Announces First Dosing in Phase 2 Trial for OK-101 to Treat Neuropathic Corneal Pain
MP3•Episod hem
Manage episode 446656547 series 2891889
Innehåll tillhandahållet av Proactive Investors. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Proactive Investors eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
OKYO Pharma CEO Gary Jacob joined Steve Darling from Proactive to share news the company is reporting the first patient has been dosed in the Phase 2 trial of OK-101, a topical ocular treatment for neuropathic corneal pain (NCP). This double-masked, randomized, 12-week placebo-controlled trial will enroll 48 patients, all of whom will have their NCP disease confirmed via confocal microscopy. The trial is being conducted at a single center under the leadership of Dr. Pedram Hamrah from Tufts Medical Center, where he serves as Professor and Vice Chair of Research and Academic Programs, and Director of the Center for Translational Ocular Immunology. Dr. Hamrah’s expertise will guide the study, which aims to evaluate the effectiveness of OK-101 in alleviating pain caused by corneal nerve damage—a condition with no current FDA-approved treatments. Jacob highlighted that OK-101 is a novel, non-opioid therapeutic specifically designed to target the severe and often debilitating pain associated with NCP. This condition can stem from various sources, including dry eye disease, surgery, or infections, and can significantly affect patients' quality of life. Presently, treatment options for NCP are limited to temporary pain relief strategies that often fall short of providing long-term relief. OKYO Pharma’s development of OK-101 is a promising step toward addressing this unmet medical need, potentially offering patients a more effective solution to manage their corneal pain. #proactiveinvestors #okyopharmalimited #nasdaq #okyo #NeuropathicPain #OcularPain #OK101Trial #FDAApproval #Biotech #Pharmaceuticals #ClinicalTrial #DrugDevelopment #HealthInnovation#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
609 episoder
Alla avsnitt
×Välkommen till Player FM
Player FM scannar webben för högkvalitativa podcasts för dig att njuta av nu direkt. Den är den bästa podcast-appen och den fungerar med Android, Iphone och webben. Bli medlem för att synka prenumerationer mellan enheter.